I read with great interest the recent article "Artesunate inhibits growth and induces apoptosis in human osteosarcoma HOS cell line in vitro and in vivo" by Xu et al. (2011) , published in Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology) . Artesunate exerts anti-neoplastic effects in a number of systemic malignancies besides osteosarcomas.
Artesunate exerts anti-proliferative effects in pulmonary adenocarcinomas. It mediates these antineoplastic effects by virtue of activating Bak . At the same time, it down-regulates epidermal growth factor receptor expression. This results in augmented non-caspase dependent apoptosis in the adenocarcinoma cells. Artesunate mediated apoptosis is time as well as dose dependent. Interestingly, AIF and Bim play significant roles in this Bak-dependent accentuated apoptosis (Ma et al., 2011) . Adenosine triphosphate (ATP)-binding cassette subfamily G member 2 (ABCG2) expression is also attenuated while transcription of matrix metallopeptidase 7 (MMP-7) is also down-regulated (Zhao et al., 2011) . In addition, arsenuate enhances the radiosensitization of lung carcinoma cells. It mediates this effect by down-regulating cyclin B1 expression, resulting in augmented G 2 /M phase arrest (Rasheed et al., 2010) .
Similarly, artesunate exhibits anti-neoplastic effects in breast carcinomas. Artesunate administration is typically accompanied by attenuated turnover as well as accentuated peri-nuclear localization of autophagosomes in the breast carcinoma cells. Mitochondrial outer membrane permeability is typically augmented. As a result, artesunate augments programmed cellular decline in breast carcinoma cells (Hamacher-Brady et al., 2011) . Lysosomal iron plays a major role in the production of reactive oxygen species (ROS). Similarly, artesunate inhibits the PI3K/Akt signaling pathway in cervical malignancies. The expression of Bcl-xL is markedly attenuated. As a result, it accentuates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induced intrinsic as well as extrinsic apoptosis in these cancers (Thanaketpaisarn et al., 2011) . It also decreases TRAIL induced nuclear factor-κB (NF-κB) activity.
Artesunate also exerts anti-neoplastic effects in skin malignancies. It mediates these effects by up-regulating p21. At the same time it downregulates cyclin D1 (Jiang et al., 2012) . Cdk4 is also down-regulated simultaneously. As a consequence there is accentuated G 0 /G 1 phase arrest. Artesunate also augments iron-dependent mitochondrial apoptosis. Similarly, artesunate enhances the radiosensitivity of tumors such as gliomas. It mediates this effect by down-regulating the expression of surviving (Reichert et al., 2012) . As a result, there is increased G 2 /M phase arrest. Intra-tumoral apoptosis is also markedly accentuated.
The above examples clearly illustrate the significant anti-proliferative and apoptosis enhancing effects of artesunate and the need for further large scale studies in this regard.
